RxDoctor Payments DataLook up a doctor →

Erik Burton

Neurology · Shreveport, LANPI 1730381179

Payments from drug & device makers

$191,917in general payments, 2019–2025

Across 1,108 payments — averaging $173.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$110K
  • Genentech, Inc.$37K
  • AstraZeneca$17K
  • EMD Serono, Inc.$9K
  • Sanofi$7K
  • AbbVie$2K
  • plus $9K from 38 others

What the payments were for

  • Consulting fees$14,1789%
  • Speaking & faculty fees$103,93867%
  • Travel & lodging$20,16713%
  • Food & beverage$16,21610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$191,917 in reported general payments places this provider in the 90th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$40,884
Medicare patients
167
Services billed
552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab231$2,124,400
MayzentSiponimod62$584,645
BetaseronInterferon Beta-1b18$167,912
Gammagard S-DImmun Glob G/Gly/Gluc/Iga 0-5013$152,583
TysabriNatalizumab18$147,977
Avonex Pen (4 Pack)Interferon Beta-1a15$119,753
Dalfampridine ErDalfampridine220$90,878
Nurtec OdtRimegepant Sulfate60$88,700
GlatopaGlatiramer Acetate26$68,171
IngrezzaValbenazine Tosylate11$41,579
MyrbetriqMirabegron72$28,895
Emgality PenGalcanezumab-Gnlm23$21,268
NuedextaDextromethorphan Hbr/Quinidine18$14,100
LinzessLinaclotide21$10,965
ReyvowLasmiditan Succinate12$8,996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMayzent$110,434$584,64562 claims
BiogenTysabri$780$147,97718 claims
PfizerNurtec Odt$680$88,70060 claims
Neurocrine Biosciences, Inc.Ingrezza$56$41,57911 claims
AbbVieLinzess$2,307$10,96521 claims
Lilly USA, LLCReyvow$118$8,99612 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$31$1,35219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 225 neurology providers in Louisiana.

Other neurology in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →